|
[1]
|
Shung-Shung S, Tih-Fang H, Shih-chuan T, et al. Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results[J]. Cancer Lett, 2000, 153(1-2):95-100. |
|
[2]
|
Del-Vecchio S, Ciarmiello A, Pace L, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients[J]. J Nucl Med, 1997, 38(9):1348-1351. |
|
[3]
|
Del-Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of multidrug-resistance (MDB1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients[J]. Eur J Nucl Med, 1997, 24(2):150-159. |
|
[4]
|
Kostakoglu L, Kirath P, Ruacan S, et al. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer[J]. J Nucl Med, 1998, 39(2):228-234. |
|
[5]
|
Andrews DW, Dss R, Kim S, et al. Technetium-MIBI as a glioma imaging agent for the assessment of multidrug resistance[J]. Neurosurgery, 1997, 40(6):1323-1332. |
|
[6]
|
Kapucu LÖ, Akyüz C, Varal G, et al. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi[J]. J Nucl Med, 1997, 38(2):243-247. |
|
[7]
|
Gruber A, Areström I, Xu D, et al. Multidrug resistance phenotype in leukaemia cells from patients with acute myelocytie leukaemia can be detected with 99Tcm-MIBI[J]. Br J Cancer, 1998, 77(11):1732-1736. |
|
[8]
|
Kostakoglu L, Guc D, Canpinar H, et al. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy[J]. J Nucl Med, 1998, 39(7):1191-1197. |
|
[9]
|
Leitha T, Glaser C, Lang S. Is early sestamibi imaging in head and neck cancer affected by MDR status, P53 expression, or cell proliferation?[J]. Nucl Med Biol, 1998, 25(6):539-541. |
|
[10]
|
Fujii H, Nakamura K, Kubo A, et al. Preoperative evaluation of the chemosensitivity of breast cancer by means of double phase 99Tcm-MIBI scintimammography[J]. Ann Nacl Med, 1998, 12(6):307-312. |
|
[11]
|
Kostakoglu L, Ruacan S, Ergün EL, et al. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer[J]. J Nucl Med, 1998, 39(6):1021-1026. |
|
[12]
|
Duran-Cordobes M, Moretti JL, De-Beco V, et al. Uptake of liposome-encapsulated 99Tcm-MIBI by sensitive and multidrug-resistant tumour cell lines[J]. Nucl Med Commun, 1999, 20(5):433-437. |
|
[13]
|
Hendrikse NH, Franssen EJF, Van-der-Graaf WTA, et al.99Tcm-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein[J]. Br J Cancer, 1998, 77(3):353-358. |
|
[14]
|
Moretti JL, Duran-Cordobes M, Starzec A, et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells[J]. J Nucl Med, 1998, 39(7):1214-1218. |
|
[15]
|
Chia-Hung K, Shih-Chuan T, Tse-Jia L, et al. P-glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings[J]. Cancer Res, 2001, 61(4):1412-1414. |
|
[16]
|
Chia-Hung K, Shih-Chuan T, Thi-Joung W, et al. Technetium-99m-sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression multidrug resistance-related protein expression and other prognosis factors[J]. Br J Haematol, 2001, 113(2):369-374. |
|
[17]
|
Zhou J, Higashi K, Ueda Y, et al. Expression of multidrug resistance protein and messenger RNA correlate with 99Tcm-MIBI imaging in patients with lung cancer[J]. J Nucl Med, 2001, 42(10):1476-1483. |
|
[18]
|
Kabasakal L, Özker K, Hayward M, et al. Technetium-99m sestamibi uptake in human breast carinoma cell lines displaying glutathione-associated drug-resis tance[J]. Eur J Nucl Med, 1996, 23(5):568-570. |
DownLoad: